Compound Detail
CHEMBL844
BRIMONIDINE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL844 |
| Name | BRIMONIDINE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | XYLJNLCSTIOKRM-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
17
Targets
49
Activities
3
Assay Types
0
PK Parameters
20
Publications
6
Known Names
8
Indications
Molecular Properties
292.1
MW (Da)
1.76
ALogP
5
HBA
2
HBD
62.2
PSA (Ų)
0.84
QED
0
Ro5 Violations
1
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1996 |
| Availability | OTC |
| Chirality | Achiral |
Indications
Eye Manifestations Glaucoma Ocular Hypertension Rosacea Diabetic Retinopathy Dry Eye Syndromes Glaucoma, Open-Angle Presbyopia
ATC Classification
D11AX21
brimonidine
Level 1: DERMATOLOGICALS
Level 2: OTHER DERMATOLOGICAL PREPARATIONS
S01EA05
brimonidine
Level 1: SENSORY ORGANS
Level 2: OPHTHALMOLOGICALS
S01GA07
brimonidine
Level 1: SENSORY ORGANS
Level 2: OPHTHALMOLOGICALS
Activity Summary
Ki 24 meas. best 8.85
EC50 13 meas. best 9.21
IC50 12 meas. best 8.52
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Alpha-2A adrenergic receptor CHEMBL1867 | EC50 | 9.21 | 8.89 | 0.6 | 3 |
| Unchecked CHEMBL612545 | Ki | 8.85 | 8.08 | 1.4 | 2 |
| Adrenergic receptor alpha-2 CHEMBL2095158 | Ki | 8.85 | 8.6967 | 1.4 | 3 |
| Alpha-2A adrenergic receptor CHEMBL1867 | Ki | 8.57 | 7.8967 | 2.7 | 3 |
| Adrenergic receptor alpha-2 CHEMBL2095158 | IC50 | 8.52 | 8.52 | 3.0 | 1 |
| Alpha-2C adrenergic receptor CHEMBL1916 | EC50 | 8.47 | 8.1967 | 3.4 | 3 |
| Adrenergic receptor alpha-2 CHEMBL2093864 | IC50 | 8.44 | 8.44 | 3.6 | 1 |
| Adrenergic receptor alpha-2 CHEMBL2093864 | Ki | 7.52 | 7.52 | 30.0 | 1 |
| Alpha-2B adrenergic receptor CHEMBL1942 | Ki | 7.46 | 6.89 | 34.7 | 2 |
| Alpha-2C adrenergic receptor CHEMBL1916 | Ki | 7.36 | 7.22 | 44.0 | 2 |
| Alpha-2B adrenergic receptor CHEMBL266 | Ki | 7.28 | 7.28 | 52.0 | 1 |
| Alpha-2B adrenergic receptor CHEMBL266 | EC50 | 7.26 | 7.26 | 55.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 7.13 | 7.13 | 74.0 | 1 |
| Alpha-2B adrenergic receptor CHEMBL1942 | EC50 | 6.55 | 6.55 | 281.8 | 1 |
| Alpha-2A adrenergic receptor CHEMBL1867 | IC50 | 6.53 | 6.53 | 298.0 | 1 |
| Adrenergic receptor alpha-1 CHEMBL1907610 | Ki | 6.13 | 6.13 | 740.0 | 1 |
| Alpha-1D adrenergic receptor CHEMBL223 | Ki | 6.07 | 6.05 | 846.0 | 2 |
| Alpha-1B adrenergic receptor CHEMBL3988626 | EC50 | 6.03 | 6.03 | 943.0 | 1 |
| Alpha-2B adrenergic receptor CHEMBL1942 | IC50 | 5.98 | 5.98 | 1047.0 | 1 |
| Alpha-1A adrenergic receptor CHEMBL4892 | EC50 | 5.95 | 5.95 | 1132.0 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL273 | Ki | 5.84 | 5.84 | 1458.0 | 1 |
| Alpha-1D adrenergic receptor CHEMBL223 | IC50 | 5.76 | 5.76 | 1720.0 | 1 |
| Adrenergic receptor alpha-1 CHEMBL2094251 | Ki | 5.75 | 5.73 | 1800.0 | 3 |
| Adrenergic receptor alpha-1 CHEMBL1907610 | IC50 | 5.62 | 5.62 | 2400.0 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL273 | IC50 | 5.59 | 5.59 | 2551.0 | 1 |
| Alpha-1A adrenergic receptor CHEMBL319 | Ki | 5.59 | 5.59 | 2568.0 | 1 |
| Alpha-1A adrenergic receptor CHEMBL229 | Ki | 5.55 | 5.55 | 2818.4 | 1 |
| Alpha-1B adrenergic receptor CHEMBL232 | Ki | 5.27 | 5.27 | 5370.3 | 1 |
| Alpha-1A adrenergic receptor CHEMBL319 | IC50 | 5.2 | 5.2 | 6344.0 | 1 |
| Plasmodium falciparum CHEMBL364 | IC50 | 5.1 | 5.0333 | 7943.3 | 3 |
| Unchecked CHEMBL612545 | EC50 | 4.94 | 4.94 | 11400.0 | 1 |
| Adrenergic receptor alpha-2 CHEMBL2095158 | EC50 | 4.94 | 4.94 | 11400.0 | 2 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 16472241 | 10.2174/1570163043334794 | Hepatotoxicity | 18 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 4 |
| 2567783 | 10.1021/jm00127a037 | Rattus norvegicus | 4 |
| - | 10.1016/0960-894X(95)00391-6 | Alpha-2A adrenergic receptor | 3 |
| 9016324 | 10.1021/jm9605142 | Alpha-2C adrenergic receptor | 3 |
| 9016324 | 10.1021/jm9605142 | Alpha-2B adrenergic receptor | 3 |
| 9016324 | 10.1021/jm9605142 | Alpha-2A adrenergic receptor | 3 |
| - | 10.1016/0960-894X(95)00391-6 | Alpha-2B adrenergic receptor | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Nuclear receptor subfamily 1 group I member 2 | 3 |
| - | 10.1016/0960-894X(95)00391-6 | Alpha-2C adrenergic receptor | 3 |
| 19734910 | 10.1038/nchembio.215 | Plasmodium falciparum | 3 |
| - | 10.6019/CHEMBL4495564 | Replicase polyprotein 1ab | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| 19133776 | 10.1021/jm800838r | Adrenergic receptor alpha-2 | 2 |
| 18459731 | 10.1021/jm800026x | Unchecked | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Peroxisome proliferator-activated receptor gamma | 2 |
| 6264080 | 10.1021/jm00137a006 | Adrenergic receptor alpha | 2 |
| 17691718 | 10.1021/jm070229q | Adrenergic receptor alpha-2 | 2 |
Data from ChEMBL 36 via Core Engine